HIV-1 vaccine candidate evaluation in non-human primates

Critical Reviews in Oncogenesis

Volumn 8, Issue 2-3, 1997, Pages 273-291

  Lu, Yichen ^a  

^a Inst for Intl Vacc Devmt Inc   (United States)

Author keywords

AIDS vaccine efficacy; Animal models; HIV I vaccine candidates; Non human primates; Recombinant BCG vectors; Recombinant HIV 1 gp120; Recombinant viral vectors; Whole inactivated virus

Indexed keywords

BCG VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHIMPANZEE; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MONKEY; NONHUMAN; PRIMATE; REVIEW; VACCINATION;

EID: 0031448091     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v8.i2-3.50     Document Type: Review

References (70)

1. Alter, H. J., J. W. Eichberg, H. Masur, W. C. Saxinger, A. M. Macher, H. C. Lane, and A. S. Fauci: Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science, 226:549-552 (1984).
2. Amad, Z., K. K. Murthy, K. W. Higgins, N. L. Haigwood, E. K. Cobb, and K. S. Steimer: HIV-SF2 challenge of chimpanzees immunized with recombinant native HIV-SF2. J. Med. Primatol., 23:238 (1994).
3. Arthur, L. O., J. W. Bess, D. J. Waters, S. W. Pyle, J. C. Kelliher, P. L. Nara, K. Krohn, W. G. Robey, A. J. Langlois, R. C. Gallo, and P. J. Fischinger: Challenge of chimpanzees (pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J. Virol, 63:5046-5053 (1989).
4. Barnett, S. W., J. M. Klinger, H. Legg, P. A. Luciw, M. Murphey-Corb, and K. S. Steimer: Recombinant gp120 SF2/MF59 subunit immunization does not protect rhesus macaques from intravenous challenge with heterologous SHIV33. In: Program Book of 8th Annual Meeting of NCVDG for AIDS, p. 126 (1996).
5. Barre-Sinoussi, F., J. C. Cherman, F. Ray, M. T. Nugeyre, S. Chemaret, G. Gruest, C. Dauguet, C. Axler-Blin, C. Vezinet-Brun, W. Rouzioux, W. Rozenbaum, and L. Montagier: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 220:868-871, 1983
6. Barker, L. F., F. A. Chisari, P. P. McGrath, D. W. Dalgard, R. L. Kirschtein, J. D. Almeida, T. S. Edgington, D. G. Sharp, and M. R. Peterson: Transmission of type viral hepatitis to chimpanzees. J. Infect. Dis., 127:648-662 (1973).
7. Beasley, R. P., L.-Y. Hwang, G. C.-Y. Lee, C.-C. Lan, C.-H. Roan, F.-Y. Huang, and C.-L. Chen: Prevention of perinatally hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet, 2:1099-1102(1983).
8. Berman, P. W., G. E. Groopman, T. Gregory, P. R. Clapham, R. A. Weiss, R. Ferriani, R. Riddle, C. Shamasaki, C. Lucas, L. Lasky, and J. W. Eichberg: Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoproteins gp120. PNAS, 85:5200-5204 (1988).
9. Berman, P. W., T. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature, 345:622-625 (1990).
10. Berman, P. W., K. K. Murthy, T. Wrin, J. C. Vennari, E. K. Cobb, D. J. Eastman, M. Champe, G. R. Nakamura, D. Davison, M. F. Powell, J. Bussiere, D. P. Francis, T. Matthews, T. J. Gregory, and J. F. Obijeski: Protection of MN-rgpl20-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis., 173:52-59 (1996).
11. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, L. Gilbert, M. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. A. Williams, Y. Refaeli, R. B. Ciccarelli, D. McCallus, L. Coney, and D. B. Weiner: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Medicine, 3:526-532 (1997).
12. Bruck, C., C. Thiriart, L. Fabry, M. Francotte, P. Pala, O. Van Opstal, J. Culp, M. Rosent, M. De Wilde, P. Heidt, and J. Heeney: HIV-1 envelope-elicited neutralizing antibody titers correlate with protection and virus load in chimpanzees. Vaccine, 12:1141-1148 (1994).
13. Cameron, J. D.: Infective hepatitis. Quart. J. Med. N. S., 12:139(1943).
14. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan: An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol, 66:7517-7521 (1992).
15. Crosnier, J., P. Jungers, A. M. Courouce, A. Laplanche, E. Benhamou, F. Degos, B. Lacour, P. Prunet, Y. Cerisier, and P. Guesry: Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis unit: Haemodialysis patients. Lancet, 1:797-800 (1981).
16. Desmyter, J., J. Colaert, G. De Groote, M. Reynders, E. E. Reerink-Brongers, P. N. Lelie, P. J. Dees, and H. W. Reesink: Efficacy of heat inactivated hepatitis B vaccine in hemodialysis patients and staff. Lancet, 2:1323-1327 (1983).
17. Edgington, S. M.: Biotech Vaccine's problematic promise. Bio/technology, 10:763-766 (1992).
18. Emini, E. A., P. L. Nara, W. A. Schleif, J. A. Lewis, J. P. Davide, D. R. Lee, J. Kessler, S. Conley, S. Matstushita, S. T. Putney, R. J. Gerety, and J. W. Eichberg: Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol., 64:3674-3678 (1990a).
19. Emini, E. A., W. A. Schleif, J. C. Quintero, P. G. Conard, J. W. Eichberg, G. P. Vlasuk, E. D. Lehman, M. A. Polokoff, T. F. Schaeffer, L. D. Schultz, K. J. Hofmann, J. A. Lewis, and V. M. Larson: Yeast expressed p55 pre-cursor core protein of human immunodeficiency virus type 1 does not elicit protective immunity in chimpanzees. AIDS Res. Human Retroviruses, 6:1246-1250 (1990b).
20. Fultz, P. N., H. M. McClure, R. B. Swenson, C. R. McGrath, A. Brodie, J. P. Getchell, F. C. Jensen, D. C. Anderson, R. Broderson, and D. P. Francis: Persistent infections of chimpanzees with human T-lymphotropic virus type III /lymphadenopathy-associated virus: a potential model for acquired immune deficiency syndrome. J. Virol., 58:116-124 (1986a).
21. Fultz, P. N., H. M. McClure, H. Daugharty, A. Brodie, C. McGrath, B. Swenson, and D. Francis: Vaginal transmission of Immunodeficiency virus (HIV) to a chimpanzee. J. Infect. Dis., 154:896-900 (1986b).
22. Fultz, P. N., P. Nara, F. Barre-Sinoussi, A. Chaput, M. L. Greenberg, E. Muchmore, M.-P. Kieny, and M. Girard: Vaccine protection of chimpanzees against challenge with HIV-1 -infected peripheral blood mononuclear cells. Science, 256:1687-1689 (1992).
23. Gallo, R. C., S. Z. Salahuddin, M. Popovic, G. M. Shearer, M. Kaplan, B. F. Haynes, T. J. Palker, R. Redfield, J. Oleske, B. Safai, G. White, P. Foster, and P. D. Markham: Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science, 220:865-867 (1983).
24. Gibbs, C. J., R. Peters, M. Gravell, B. K. Johnson, F. Jensen, D. J. Carlo, and J. Salk: Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees. PNAS, 88:3348-3352 (1991 ).
25. Girard, M., M.-P. Kieny, J.-C. Gluckman, F. Barre-Sinoussi, L. Montagnier, and P. N. Fultz: Candidate Vaccine for HIV. In: Vaccine for sexual transmitted diseases (A. Meheus and R. E. Spier, Eds.) Butterworths, London, 227-237 (1989).
26. Girard, M., M.-P. Kieny, A. Pinter, F. Barre-Sinoussi, P. Nara, H. Kolbe, K. Kusumi, A. Chaput, T. Reinhart, E. Muchmore, J. Ronco, M. Kaczorek, E. Gomard, J.-C. Gluckman, and P. N. Fultz: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. PNAS, 88:542-546 (1991).
27. Girard, M., B. Meignier, F. Barre-Sinoussi, M.-P. Kieny, T. Matthews, E. Muchmore, P. L. Nara, Q. Wei, L. Rimsky, K. Weinhold, and P. N. Fultz: Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol., 69:6239-6248 (1995).
28. Girard, M., L. Yue, F. Barre-Sinoussi, E. Van der Ryst, B. Meignier, E. Muchmore, and P. N. Fultz: Failure of a human immunodeficiency virus type 1 subtype B-derived vaccine to prevent infection of chimpanzees by anHIV-1 subtype E strain. J. Virol., 70:8229-8233 (1996).
29. Girard, M., E. Van der Ryst, F. Barre-Sinoussi, P. Nara, J. Tartaglia, E. Paoletti, C. Blondeau, M. Jennings, F. Verrier, B. Meignier, and P. N. Fultz: Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus. Virology, 232:98-104 (1997a).
30. Girard, M., F. Barre-Sinoussi, E. Van de Ryst, F. Verrier, C. Moog, and A. M. Aubertin: Lack of vaccine protection against experimental SHIV infection in rhesus macaques. In: Program Book of 9th Annual Meeting of NCVDG for AIDS, p. 75 (1997b).
31. Gottlieb, M. S., R. Schroff, H. M. Schanker et al.: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N. Engl. J. Med., 305:1425-1431, 1981
32. Honda, M., Y. Amy, S. Kenji, S. Ando, K. Matsuo, Y. Lu, and S. Yamazaki: Recombinant BCG vector-based vaccine trial to SHIV challenge. In: Program Book of 8th Annual Meeting of NCVDG for AIDS, p. 164 (1996).
33. Hu, S. L., P. N. Fultz, H. M. McClure, J. W. Eichberg, E. K. Thomas, J. Zarling, M. C. Singhai, S. G. Kosowski, R. B. Swenson, D. J. Anderson, and G. Todaro: Effect of immunization with a vaccinia-HIV env recombinant in HIV infection of chimpanzees. Nature, 328:721-724 (1987).
34. Hu, S. L., J. E. Klaniecki, B. M. Travis, T. Wrey, S. Pennathur, J. L. Thompson, M. B. Agy, L. Kuller, Y. Lu, D. Montefiori, and W. R. Morton: Protection against SHIVIIIB challenge by the "prime/boost" regimen. In: Program Book of 9th Annual Meeting of NCVDG for AIDS, p. 69 (1997).
35. Joag, S. J., I. Adany, Z. Li, L. Foresman, D. Pinson, C. Wang, E. Syephens, R. Raghavan, and O. Narayan: Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells and AIDS. J. Virol., 71:4016-4023 (1997).
36. Karlsson, G. B., M. Halloran, J. Li, I.-W. Park, R. Gomila, K. A. Reimann, M. K. Axthelm, S. A. Iliff, N. L. Letvin, and J. Sodroski: Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J. Virol., 71:4218-4225 (1997).
37. Lasky, L., J. Groopman, C. Fennie, P. Benz, D. Capon, D. Dowbenco, G. Nakamura, W. Nunes, M. Renz, and P. Berman: Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science, 233:209-212 (1986).
38. Lewis, M. G., F. Novembre, R. Desrosiers, Y. Lu, D. Montefiori, J. Yalley-Ogunro, J. Greenhouse, T. Brennan, and G. Eddy: Attenuated SIV vaccine: degree of protection from homologous and heterologous challenge. In: Program Book of 9th Annual Meeting of NCVDG for AIDS, p. 88 (1997).
39. Letvin, N. L., C. I. Lord, N. W. King, M. S. Wyand, K. Myrick, and W. A. Haseltine: Risks of handling HIV. Nature, 349:573 (1991).
40. Letvin, N., D. Montefiori, Y. Yasutomi, H. Perry, M.-E. Davies, C. Lekutis, M. Alroy, D. Freed, C. Lord, L. Handt, M. Liu, and J. Shiver: Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. PNAS, 94:9378-9383 (1997).
41. Li, J., C. Lord, W. Haseltine, N. Letvin, and J. Sodroski: Infection of cynomolgus monkeys with a chimeric HIV1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. JAIDS, 5:639-646 (1992).
42. Liu, M. A., N. Letvin, D. Montefiori, Y. Yasotomi, H. Perry, M.-E. Dacies, C. Lekutis, M. Alroy, D. Freed, C. Lord, L. Handt, and J. Shiver: Bimodal HIV env DNA+protein immunization generates potent immune responses and protect against SHIV challenge. In: Program Book of 9th Annual Meeting of NCVDG for AIDS, p. 59 (1997).
43. Lu, Y., M. Salvato, C. D. Pauza, J. Li, J. Sodroski, K. Manson, M. Wyand, N. Letvin, S. Jenkins, N. Touzjian, C. Chutkowski, N. Kushner, M. LeFaile, L. Payne, and B. Roberts: Utility of SHIV for testing HIV-1 vaccine candidates in macaques. JAIDS, 12:99-106 (1996a).
44. Lu, Y., B. Brosio, M. LaFaile, J. Li, R. G. Collman, J. Sodroski, and C. J. Miller: Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques. J. Virol., 70:3045-3050 (1996b).
45. Lu, Y., C. D. Pauza, X. Lu, and C. J. Miller: Rhesus macaques that become systematically infected with pathogenic SHIV-89.6PD after intravenous, rectal or vaginal inoculation, and fail to make an antiviral antibody response, rapidly develop AIDS. (1998, submitted).
46. Lubeck, M. D., R. Natuk, M. Myagkikh, N. Kalyan, K. Aldrich, F. Sinangil, S. Alipanah, S. C. Murthy, P. K. Chanda, S. M. Nigida, P. D. Markham, S. Zolla-Pazner, K. Steimer, M. Wade, M. S. Reitz, L. O. Arthur, S. Mizutani, A. Davis, P. P. Hung, R. C. Gallo, J. W. Eichberg, and M. Robert-Guroff: Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Medicine, 3:651-658 (1997).
47. Luciw, P. A., E. Pratt-Lowe, K. E. Shaw, J. A. Levy, and C. Cheng-Mayer: Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage tropic clones of simian/human immunodeficiency viruses (SHIV). PNAS, 92:7490-7494 (1995).
48. Mannhalter, M. L., N. Barrett, Z. Kupcu, O. Kistner, H. M. Wolf, K. Huber, G. Eder, F. Dorner, R. C. Gallo, B. Moss, and M. M. Eibl: Immunological parameters associated with protection against challenge with HIV-1 in rgp160 immunized chimpanzees. Abstract. VII International Conference on AIDS, Th.A. 13:59 (1991).
49. McCallum, F. O. and W. H. Bradley: Transmission of infectious hepatitis to human volunteer. Lancet, 2:228 (1944).
50. Miller, C. J., M. B. McChesney, X. S. Lu, P. J. Dailey, C. Chutkowski, D. Lu, P. Brosio, B. Roberts, and Y. Lu: Rhesus macaques previously-infected with SHIV are protected from vaginal challenge with pathogenic SIVmac239. J. Virol., 71:1911-1921 (1997).
51. Montefiori, D. C., P. L. Earl, B. Moss, S.-L. Hu, M. Lewis, T. C. Vancott, D. L. Birx, M. S. Wyand, K. Manson, J. W. Shiver, K. A. Reimann, and N. L. Letvin: Neutralizing antibodies as correlate of vaccine efficacy in the SHIV model. In: Program Book of 9th Annual Meeting of NCVDG for AIDS, p. 68 (1997).
52. Nara, P. L., W. G. Robey, L. O. Arthur, D. M. Asher, A. V. Wolff, C. J. Gibbs, D. C. Gajdusek, and P. J. Fischinger: Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of re-isolated viruses. J. Virol., 61:3173-3180 (1987).
53. Natuk, R. J., M. D. Lubeck, P. K. Chanda, M. Chengalvala, M. Wade, S. C. Murthy, J. Wilhelm, S. K. Vernon, S. K. Dheer, S. Mizutani, S.-G. Lee, K. K. Murthy, J. W. Eichberg, A. R. Davis, and P. P. Hung: Immunogenecity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Hum. Retroviruses, 9:395-403 (1993).
54. Niedrig, M., J.-P. Gregersen, P. N. Fultz, M. Broker, S. Mehdi, and J. Hilfenhaus: Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine, 11:67-74 (1993).
55. Novembre, F. J., M. Saucier, D. C. Anderson, S. A. Klumpp, S. P. O'Neil, C. R. Brown, C. E. Hart, P. C. Guentthner, R. B. Swenson, and H. M. McClure: Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J. Virol., 71:4086-4091 (1997).
56. Prince, A. M., B. Horowitz, L. Baker, R. W. Shulman, R. Ralph, J. Valinsky, A. Cundell, B. Brotman, B. Boehle, F. Rey, M. Piet, H. Reesink, N. Lelie, M. Tersmette, F. Miedema, L. Barbosa, G. Nemo, C. L. Nastala, J. S. Allan, D. R. Lee, and J. W. Eichberg: Failure of a human immunodeficiency virus immune globulin to protect chimpanzees against experimental challenge with HIV. PNAS, 85:6944-6948 (1988).
57. Purcell, R. H. and J. L. Gerin: Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am. J. Med. Sci., 270:395-399 (1975).
58. Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin: A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol., 70:6922-6928 (1996).
59. Richieri, S. P., R. Bartholomew, R. C. Aloia, J. Savary, R. Gore, J. Holt, F. Ferre, R. Musil, H. R. Tian, R. Trauger, P. Lowry, F. Jensen, D. Carlo, R. Z. Maigetter, and C. P. Prior: Characterization of highly purified inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine, 16:119-129 (1998).
60. Sakuragi, S., R. Shibata, R. Mukai, T. Kumatsu, M. Fukasawa, H. Sakai, J.-I. Sakuragi, M. Kawamura, K. Ibuki, M. Hayami, and A. Adachi: Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. J. Gen. Virol., 73:2983-2987 (1992).
61. Shibata, R., M. Kawamura, H. Sakai, M. Hayami, A. Ishimoto, and A. Adachi: Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol., 65:3514-3520 (1991).
62. Spouge, J. L.: Statistical analysis of sparse infection data and its implication for retro viral treatment trials in primates. PNAS, 89:7581-7585 (1992).
63. Stevens, C. E., P. T. Toy, M. J. Tong, P. E. Taylor, G. N. Vyas, P. V. Nair, M. Gudavalli, and S. Krugman: Perinatal hepatitis B virus transmission in the United States: prevention by passive-active immunization. J.A.M.A., 253:1740-1745 (1985).
64. Struck, M.-M.: Vaccine R&D success rates and development times. Nature Biotechnology, 14:591-593 (1996).
65. Szmuness, W., C. E. Stevens, E. J. Harley, E. A. Zang, W. R. OLeszko, D. C. William, R. Sadovsky, J. M. Morrison, and A. Kellner: Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in high risk population in the United States. N. Engl. J. Med., 303:833-842 (1980).
66. Van Eendenberg, J. P., M. Yagello, M. Girard, M.-P. Kieny, J.-P. Lecocq, E. Muchmore, P. N. Fultz, Y. Riviere, L. Montagnier, and J.-C. Gluckman: Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Res Hum Retroviruses, 5:41-50 (1989).
67. VanCott, T. C., M. Lewis, R. Kaminski, J. Mascola, V. Kalyanaraman, S. Pragman, M. Frampton, J. YalleyOgunro, J. Greenhouse, Y. Lu, S. Jenkins, J. Richardson, T. Ulrich, N. Wassef, C. Alving, G. Lowell, and D. Birx: Protection of rhesus macaques from homologous and heterologous SHIV challenge using oligomeric gp160. In: Program Book of 9th Annual Meeting of NCVDG for AIDS, p. 152 (1997).
68. Voegt, H.: Zur Aetiologie Hepatitis epidemica. Munch. Med. Wochenschr, 89:76 (1942).
69. Weiner, D. B.: Gene inoculation as a tool to develop protective responses in vivo. In a plenary presentation to "Vaccine, new technologies & applications", Cambridge Healthtech Institute, March 21-23 (1994).
70. Wyand, M.: Vaccine studies with SHIV IIIB. Abstract. In: 8th Annual Meeting of NCVDG for AIDS, NIH contract #N01-AI-15114. Contact Mike Wyand at telephone: 508-890-0100 for copies (1996).